ReviewCells2026
Neutrophil Extracellular Traps at the Asthma + COPD Interface: Mechanisms, Experimental Models, and Therapeutic Targeting.
Review in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma and chronic obstructive pulmonary disease (COPD) are distinct chronic airway diseases with different pathophysiological mechanisms, but they may coexist and share clinical, functional, inflammatory, and structural features. The historical terminology used to describe this coexistence has shifted away from the notion of a single overlap syndrome toward a traits-based framework, emphasizing coexisting clinical, functional, inflammatory, and structural features rather than a uniform disease entity. Within this context, neutrophil extracellular traps (NETs) are emerging as a potential mechanistic link between allergic airway inflammation, cigarette smoke injury, neutrophilic activation, mucus obstruction, and tissue remodeling. Animal models combining allergen exposure with cigarette smoke, lipopolysaccharide, infection, or elastase provide useful platforms to dissect specific components of the asthma-COPD interface. This review examines NET biology with a primary focus on animal models that reproduce overlapping asthma and COPD features, emphasizing how epithelial injury, oxidative stress, protease activity, neutrophilic inflammation, and inflammatory cytokine networks converge to promote NET formation. NETs, composed of extracellular deoxyribonucleic acid (DNA), citrullinated histone H3, myeloperoxidase, neutrophil elastase, and granular proteins, may amplify mucus viscosity, epithelial damage, innate immune activation, airway remodeling, emphysema-like injury, and persistent airflow limitation. Strategies to target this axis include deoxyribonuclease I (DNase I), peptidylarginine deiminase 4 (PAD4) inhibition, neutrophil elastase and myeloperoxidase blockade, antioxidant approaches, C-X-C motif chemokine receptor 2 (CXCR2) modulation, and interleukin-17 (IL-17) inhibition. These interventions act at distinct stages of neutrophil recruitment, NET formation, NET persistence, or NET-mediated tissue injury. A rigorous interpretation of these models requires precise terminology, multiparametric NET detection, and integration of lung mechanics, histology, inflammatory profiling, and structural outcomes. Targeting NETs may help shift preclinical research from broad overlap labels toward mechanism-driven therapeutic strategies for coexisting asthma and COPD features.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.